Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

Inclusion Criteria:

* Participants with either unresectable or metastatic melanoma positive for the BRAF\^V600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, and for whom vemurafenib is an accepted standard of care or where there is no other generally accepted standard of care
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
* Life expectancy greater than or equal to (\>/=) 12 weeks
* Full recovery from the effects of any major surgery or significant traumatic injury within 14 days from the first dose of study drug
* Adequate hematologic and end organ function as defined by laboratory results obtained within 2 weeks prior to administration of study drug on Day 1
* Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use two effective methods of contraception during the study and at least 6 months after completion of the study drug
* Negative serum pregnancy test results within 7 days prior to Day 1 in women of childbearing potential
* Absence of any psychological, familial, or sociological condition, or geographical constraints that could potentially hamper compliance with the study protocol and follow-up schedule

Exclusion Criteria:

* Prior anti-cancer therapy before the administration of study drug on Day 1
* Invasive malignancy other than BRAF mutant melanoma or other qualifying malignant tumor with BRAF\^V600 mutation within the past 5 years
* History of clinically significant cardiac or pulmonary dysfunction
* Active central nervous system lesions
* Current, severe, uncontrolled systemic disease
* Inability or unwillingness to swallow tablets
* History of malabsorption, stomach or intestinal surgery/resection, or other condition that would potentially alter absorption and/or excretion of orally administered drugs
* History of clinically significant liver disease
* Active autoimmune disease
* Uncontrolled ascites requiring weekly large-volume paracentesis for 3 consecutive weeks prior to enrollment
* Pregnancy, lactation, or breastfeeding
* Need to take a concomitant medication, dietary supplement, or food that is prohibited during the study
* Known allergy or sensitivity to components of the vemurafenib formulation
* Active, uncontrolled or chronic infection requiring chronic suppressive antibiotics
* Use of any prescription medications/products, that are known to be strong cytochrome P450 (CYP)3A4 inhibitors or inducers within 2 weeks prior to Day 1
* Participation in any other investigational drug study in which receipt of an investigational study drug occurred within 30 days prior to Day 1 or within 5 times the elimination half-life of the respective drug (whichever is shorter)
* Participation in a trial involving administration of 14 C-radiolabeled compound(s) within 6 months prior to Day 1
* Poor peripheral venous access
* Any other acute or chronic condition that, in the opinion of the investigator, could limit the participant's ability to complete and/or participate in this clinical study